| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Decoy Therapeutics Inc.$4.15
-0.97 (-19.35%)
Market Cap
3.88 M
EPS
-124.04
P/E Ratio
-
Value Trade
202.23 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
749.81 K
Operating CF
-2.89 M
Total Assets
8.42 M
Total Liabilities
4.55 M
Equity
3.88 M
D/E Ratio
12,345
62.22 %
Week
29.43 %
1 Month
-23.89 %
3 Month
-21.62 %
6 Month
-99.98 %
5 Year
-100 %
All Time
Cash Data
Cash Position
7.82 M
Monthly Burn
963.00 K
Runway
5.7 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
977.27 K
52 Week Range
4.32 - 415.80
% held by Insiders
3.52 %
% held by Institutions
11.4 %
Enterprise Value
-3.94 M
Total Shares
6.38 M
Short %
0.38 %
Float Shares
6.37 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Decoy Therapeutics Inc.
3Total events
2Upcoming
1Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 1
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DCOY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DCOY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DCOY▼ -19.3%today
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Decoy Therapeutics has reported that its D-MAV candidate shows promising in vitro activity against the Ebola Zaire virus. This finding validates the company's D-MAV platform and has led to the initiation of a new program targeting filoviruses. The candidate also demonstrated effectiveness against Lassa fever virus, highlighting its potential in pandemic preparedness.
Read more →DCOY▲ +7.5%on this news
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
Decoy Therapeutics has elected Patricia Gauthier to its Board of Directors during the 2026 Annual Meeting. Gauthier, who has extensive experience in the biopharma industry, will support the advancement of Decoy's Designable Multi-Antivirals (D-MAVs) programs. Her background in commercial operations is expected to help the company effectively deliver its innovative antiviral solutions to patients.
Read more →DCOY▲ +73.8%on this news
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
Decoy Therapeutics, Inc. has announced a private placement financing agreement expected to yield approximately $3.5 million in gross proceeds. The financing includes milestone-based warrants that could provide up to an additional $14 million, contingent on regulatory approvals for clinical trials. The company aims to use these funds to advance its lead antiviral asset into clinical trials.
Read more →DCOY▼ -5.4%on this news· ran to -17% by day 1
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
Decoy Therapeutics' CEO, Rick Pierce, will participate in hVIVO's Capital Markets Day on June 11, 2026, in London. The event will focus on early clinical development and the role of human challenge trials in advancing therapeutics. Decoy is advancing its D-MAVs pipeline, targeting a clinical launch in 2027. The company aims to expedite antiviral development through strategic partnerships and innovative technology.
Read more →DCOY▼ -7.4%on this news· ran to -27% by day 3shared move
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
Decoy Therapeutics has nominated Patricia Gauthier for election to its Board of Directors. Gauthier, currently a senior executive at Moderna, brings significant experience in biomanufacturing and health partnerships. Her nomination will be voted on during the company's Annual Meeting on July 14, 2026. CEO Rick Pierce expressed confidence in her ability to advance Decoy's antiviral programs.
Read more →DCOY▼ -6.3%on this news· ran to -25% by day 3shared move
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Decoy Therapeutics has partnered with hVIVO to advance its Designable Multi-Antiviral (D-MAV) candidates into Phase 1 and Phase 2a studies. This collaboration aims to leverage hVIVO's expertise in clinical development and regulatory strategy to support Decoy's innovative approach to treating multiple respiratory viruses with a single adaptable therapeutic. The partnership is expected to streamline the transition of D-MAV candidates into clinical trials.
Read more →DCOYDecoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Decoy Therapeutics has appointed Dr. Brad Pentelute as Chair of its Scientific Advisory Board. Dr. Pentelute, a co-founder and MIT professor, will guide the scientific direction of Decoy's innovative Designable Multi-Antivirals (D-MAVs) platform. His expertise in peptide synthesis is expected to advance Decoy's clinical development efforts.
Read more →DCOY▼ -8.2%on this news
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Decoy Therapeutics has announced that it has regained compliance with Nasdaq's minimum bid price requirement as of March 31, 2026. The company is now compliant with all other listing requirements. However, it will be monitored for one year, and any future non-compliance could result in delisting.
Read more →DCOY▼ -11.3%on this news
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split CAMBRIDGE
Decoy Therapeutics Inc. has announced a 1-for-12 reverse stock split effective March 6, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement. This decision follows a stockholder meeting where the reverse split ratio was approved by the board. After the split, the total number of outstanding shares will decrease significantly, yet this won't alter stockholder ownership percentages. The reverse split is also expected to align Decoy Therapeutics' stock with market expectations, though it reflects prior challenges with share pricing.
Read more →DCOY▲ +53.4%on this news
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Decoy Therapeutics has announced a Global Access Commitment Agreement with the Gates Foundation to develop a scalable manufacturing platform for peptide-conjugate antivirals. This initiative aims to provide widespread access to therapeutics in low- and middle-income countries. The platform will enable rapid manufacturing and distribution of antiviral products, enhancing global health responses to viral outbreaks.
Read more →DCOYSalarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics Trading under DCOY to commence on
Salarius Pharmaceuticals has announced a rebranding to Decoy Therapeutics, along with a new Nasdaq ticker symbol DCOY, effective January 8, 2026. This change signifies the company's commitment to advancing next-generation peptide-conjugate therapeutics. Decoy's proprietary platform, enhanced by AI, aims to expedite candidate selection and facilitate innovative treatment development for viral and oncology targets. The company also outlines a focused plan for 2026, emphasizing the progress of its lead antiviral program and the pursuit of strategic partnerships.
Read more →DCOYREPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Shareholders of Decoy Therapeutics, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance she
Decoy Therapeutics, Inc. has reported its consolidated financial statements for the years ending December 31, 2024, and 2023. The audit opinion indicates that while the financial statements are fairly presented, the company continues to incur net losses and has substantial doubts about its ability to sustain operations in the future. The total liabilities have grown significantly, and the accumulated deficit has risen to $23,829,323. These factors raise concerns for investors regarding the company's financial stability and prospects for revenue generation.
Read more →DCOYUNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION The following unaudited pro forma consolidated combined financial information is provided to aid you in your analysis of the financial aspects of the Merger
Salarius and Decoy are undergoing a merger that involves stock-for-stock exchanges, with Decoy becoming a wholly-owned subsidiary of Salarius. The transaction requires minimum proceeds of $6.0 million from a financing offering to close. Financial adjustments will be made based on an exchange ratio anticipating Decoy's value at $28.0 million and Salarius at $4.6 million. The merger is poised to be treated as a reverse asset acquisition, with Decoy identified as the accounting acquirer, although final determinations remain subject to change.
Read more →DCOYDocument Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering HOUSTON
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) - Salarius Pharmaceuticals, Inc. (NASDAQ SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment
Read more →DCOYSalarius Announces Pricing of $5.3 Million Underwritten Public Offering HOUSTON
Salarius Announces Pricing of $5.3 Million Underwritten Public Offering HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the pricing
Read more →DCOYSalarius Announces Proposed Public Offering of Common Stock Houston, Texas
Salarius Announces Proposed Public Offering of Common Stock Houston, Texas, July 29, 2020 (GLOBE NEWSWIRE) Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has comm
Read more →DCOYSalarius Announces Pricing of $9.6 Million Underwritten Public Offering Houston, Texas
Salarius Announces Pricing of $9.6 Million Underwritten Public Offering Houston, Texas, February 7, 2020 Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an underwritten pu
Read more →DCOYSalarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement Initial Purchase of $1 Million of Salarius Shares Completed, Aspire Capital to Purchase Additional Salarius Common Stock over
Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement Initial Purchase of $1 Million of Salarius Shares Completed, Aspire Capital to Purchase Additional Salarius Common Stock over a 30-Month Span Extending into 2022 HOUSTON, October 28,
Read more →DCOYsalariusleader Salarius Pharmaceuticals Announces Senior Leadership Changes Scott Jordan Appointed Chief Business Officer; Mark Rosenblum, Appointed Interim Chief Financial Officer Houston, TX
Salarius Pharmaceuticals Announces Senior Leadership Changes Scott Jordan Appointed Chief Business Officer; Mark Rosenblum, Appointed Interim Chief Financial Officer Houston, TX - September 13, 2019 - Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical stage oncology compan
Read more →DCOYsalariusstockh Salarius Pharmaceuticals CEO Issues Letter to Stockholders Houston, TX
Salarius Pharmaceuticals CEO Issues Letter to Stockholders Houston, TX - August 12, 2019 - Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical stage oncology company targeting the epigenetic causes of cancers, today announced that its chief executive officer, David Arthur,
Read more →DCOYSalarius Pharmaceuticals Successfully Monetizes Legacy Consumer Product Completes Sale of HOTSHOT Houston, TX
Salarius Pharmaceuticals Successfully Monetizes Legacy Consumer Product Completes Sale of HOTSHOT July 24, 2019 Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it completed the sale of
Read more →DCOYSalarius Pharmaceuticals Announces Closing of Strategic Merger with Flex Pharma To Begin Trading on Nasdaq Capital Market Today Under Ticker Symbol SLRX Houston, TX
Salarius Pharmaceuticals Announces Closing of Strategic Merger Begin Trading on Nasdaq Capital Market Today Under Ticker Symbol SLRX Houston, TX July 22, 2019 Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of ca
Read more →DCOYFlex Pharma and Salarius Pharmaceuticals Announce Merger Agreement to Accelerate Clinical Development of Novel Epigenetic Therapy for Cancer Lead Candidate in Clinical Trial for Treating Ewing Sarcoma Salarius Completes
Flex Pharma and Salarius Pharmaceuticals Announce Merger Agreement to Accelerate Clinical Development of Novel Epigenetic Therapy for Cancer Lead Candidate in Clinical Trial for Treating Ewing Sarcoma Salarius Completes $6.4 Million Private Placement Conference Call and Live A
Read more →DCOYFlex Pharma Reports Year End 2014 Financial Results Conference Call Scheduled Today at 9:00 a.m. ET
Flex Pharma Reports Year End 2014 Financial Results Conference Call Scheduled Today at 9:00 a.m. ET Boston, MA - Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal l
Read more →Competitive Position
How DCOY ranks across every disease it competes inCompetitive Position is a premium feature
See how DCOY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial